Clinical Trial Update: A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating elranatamab with daratumumab and lenalidomide versus daratumumab, bortezomib, lenalidomide, and dexamethasone in newly diagnosed transp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Elranatamab (elranatamab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING